AIM: To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) for hepatocellular carcinoma (HCC). METHODS: The study population was comprised of 164 patients who were treated by TACE alone. Of these patients, 76 underwent TACE using a suspension of DDPH in lipiodol (LPD) (DDPH group), and the remaining 88 underwent TACE with an emulsion of doxorubicin (ADM) with LPD (ADM group). We compared the DDPH group with the ADM group in terms of the objective early response rate, progression free survival (PFS) and overall survival (OS). RESULTS: The objective early response rate in the DDPH group was significantly higher than that in the ADM group (54% vs 24%, P < 0.001). The PFS rate in the DDPH group was also significantly higher than that in the ADM group (P < 0.001). Moreover, the OS in the DDPH group was significantly longer than that in the ADM group (P = 0.002). Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group, the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia. No other serious complications were observed in either group. CONCLUSION: We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC.
AIM: To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) for hepatocellular carcinoma (HCC). METHODS: The study population was comprised of 164 patients who were treated by TACE alone. Of these patients, 76 underwent TACE using a suspension of DDPH in lipiodol (LPD) (DDPH group), and the remaining 88 underwent TACE with an emulsion of doxorubicin (ADM) with LPD (ADM group). We compared the DDPH group with the ADM group in terms of the objective early response rate, progression free survival (PFS) and overall survival (OS). RESULTS: The objective early response rate in the DDPH group was significantly higher than that in the ADM group (54% vs 24%, P < 0.001). The PFS rate in the DDPH group was also significantly higher than that in the ADM group (P < 0.001). Moreover, the OS in the DDPH group was significantly longer than that in the ADM group (P = 0.002). Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group, the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia. No other serious complications were observed in either group. CONCLUSION: We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC.
Authors: H Kasugai; J Kojima; M Tatsuta; S Okuda; Y Sasaki; S Imaoka; M Fujita; S Ishiguro Journal: Gastroenterology Date: 1989-10 Impact factor: 22.682
Authors: G Fattovich; G Giustina; F Degos; F Tremolada; G Diodati; P Almasio; F Nevens; A Solinas; D Mura; J T Brouwer; H Thomas; C Njapoum; C Casarin; P Bonetti; P Fuschi; J Basho; A Tocco; A Bhalla; R Galassini; F Noventa; S W Schalm; G Realdi Journal: Gastroenterology Date: 1997-02 Impact factor: 22.682
Authors: T Kanematsu; T Furuta; K Takenaka; T Matsumata; Y Yoshida; T Nishizaki; K Hasuo; K Sugimachi Journal: Hepatology Date: 1989-07 Impact factor: 17.425
Authors: T Imaeda; Y Yamawaki; M Seki; H Goto; G Iinuma; M Kanematsu; R Mochizuki; H Doi; S Saji; K Shimokawa Journal: Cardiovasc Intervent Radiol Date: 1993 Jul-Aug Impact factor: 2.740
Authors: S Kawai; J Okamura; M Ogawa; Y Ohashi; M Tani; J Inoue; Y Kawarada; M Kusano; Y Kubo; C Kuroda Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333
Authors: G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche Journal: J Hepatol Date: 1998-07 Impact factor: 25.083